Optimize radiochemotherapy in pancreatic cancer: PARP inhibitors a new therapeutic opportunity
about
Beyond Breast and Ovarian Cancers: PARP Inhibitors for BRCA Mutation-Associated and BRCA-Like Solid TumorsPerspectives on the combination of radiotherapy and targeted therapy with DNA repair inhibitors in the treatment of pancreatic cancerCHD7 expression predicts survival outcomes in patients with resected pancreatic cancer.PARP-1 regulates resistance of pancreatic cancer to TRAIL therapy.Aurora kinase B inhibition reduces the proliferation of metastatic melanoma cells and enhances the response to chemotherapy.Exploiting base excision repair to improve therapeutic approaches for pancreatic cancerAn evaluation in vitro of PARP-1 inhibitors, rucaparib and olaparib, as radiosensitisers for the treatment of neuroblastoma.PARP6 acts as a tumor suppressor via downregulating Survivin expression in colorectal cancer.Risk factors and therapeutic targets in pancreatic cancer.PARP-1 may be involved in angiogenesis in epithelial ovarian cancer.Pancreatic cancer: BRCA mutation and personalized treatment.Metastatic melanoma cells with BRAF G469A mutation: nab-paclitaxel better than vemurafenib?The Role of BRCA2 Mutation Status as Diagnostic, Predictive, and Prognosis Biomarker for Pancreatic Cancer.Rucaparib: First Global Approval.Four-component strategy for selective synthesis of azepino[5,4,3-cd]indoles and pyrazolo[3,4-b]pyridinesGrape seed extracts modify the outcome of oxaliplatin in colon cancer cells by interfering with cellular mechanisms of drug cytotoxicityPoly-(ADP-ribose)-polymerase inhibitors as radiosensitizers: a systematic review of pre-clinical and clinical human studies.Combination treatment with rucaparib (Rubraca) and MDM2 inhibitors, Nutlin-3 and RG7388, has synergistic and dose reduction potential in ovarian cancer.Inherited pancreatic cancer.
P2860
Q26852274-04EDD05E-B230-44C9-A8EA-A847C97BB0FCQ28066320-B14019C1-7D71-44CA-81CD-DD99194AFBCAQ33630872-A0D02B8B-57C7-4CF5-9256-0E4EBA6263B3Q33731141-17303A7F-FC88-498C-98E1-A90A854EE257Q35041273-176DC9A9-5375-4F53-8288-A5D90571BEB1Q35596477-B9953506-5490-4C51-9069-076EECEF8A12Q36102008-5BED19E5-7A47-458F-988E-00CA2F70AFF4Q37109876-D14A6FA0-71D3-4B66-AD86-AB160607A45EQ37317310-6E69EF24-A59F-4FEB-98B8-4293186E2A35Q37581637-5025371F-25F6-46D7-82DA-EE7EC91AAF1BQ38592167-C3C79001-9266-43DA-BE42-BACF7DFEE30AQ38864606-32A60FD3-B86B-4478-936B-A01BAD41A686Q39080898-4BC2C4B7-3907-4CB1-A112-0FCB4118DA76Q39155735-E35FB263-7AA4-4D00-A787-630FEF8AA4FDQ40787385-F0462202-A133-4850-94A3-88983E12F1D8Q41612485-F028611A-96CE-482F-AEA1-9F8DE28EE5F9Q42083096-E182E6F0-42A2-414A-A09E-7CB27961D727Q42378380-3744F18D-1500-4218-A759-B1B68716EDBFQ50146622-71754CC8-E872-4B5B-9223-7CC87DE1B7CD
P2860
Optimize radiochemotherapy in pancreatic cancer: PARP inhibitors a new therapeutic opportunity
description
2012 nî lūn-bûn
@nan
2012年の論文
@ja
2012年学术文章
@wuu
2012年学术文章
@zh-cn
2012年学术文章
@zh-hans
2012年学术文章
@zh-my
2012年学术文章
@zh-sg
2012年學術文章
@yue
2012年學術文章
@zh
2012年學術文章
@zh-hant
name
Optimize radiochemotherapy in ...... a new therapeutic opportunity
@en
Optimize radiochemotherapy in ...... a new therapeutic opportunity.
@nl
type
label
Optimize radiochemotherapy in ...... a new therapeutic opportunity
@en
Optimize radiochemotherapy in ...... a new therapeutic opportunity.
@nl
prefLabel
Optimize radiochemotherapy in ...... a new therapeutic opportunity
@en
Optimize radiochemotherapy in ...... a new therapeutic opportunity.
@nl
P2093
P2860
P1433
P1476
Optimize radiochemotherapy in ...... a new therapeutic opportunity
@en
P2093
Amalia Azzariti
Angelo Paradiso
Anna E Quatrale
Enza Carioggia
Jean F Rolland
Letizia Porcelli
Marco Lioce
Maria G Leo
Nicola Silvestris
Paola Mantuano
P2860
P304
P356
10.1016/J.MOLONC.2012.10.002
P577
2012-10-29T00:00:00Z